HealthQuill Overall Survival
AstraZeneca Plc’s therapy for a certain type of advanced lung cancer, in combination with chemotherapy, helped patients live longer, company data from an end-stage study reveals.
Drugs Health Pharma

AstraZeneca’s therapy for a type of lung cancer helps patients live longer 

HQ Team July 21, 2025: AstraZeneca Plc’s therapy for a certain type of advanced lung cancer, in combination with chemotherapy, helped patients live.

Read More
Merck & Co., Inc.’s drug Keytruda, along with Gilead Sciences Inc.'s antibody-drug conjugate, cut the risk of an aggressive breast cancer advancement and death by 35% during an end-stage trial.
Drugs Health Pharma

Merck, Gilead’s drug for breast cancer cuts progression risk by 35 per cent

HQ Team June 1, 2025: Merck & Co., Inc.’s drug Keytruda, along with Gilead Sciences Inc.’s antibody-drug conjugate, cut the risk of an.

Read More
Britain’s Medicines and Healthcare products Regulatory Agency has authorised GSK Plc’s combination drug to treat patients with multiple myeloma who have received at least one prior therapy.
Drugs Health Pharma

Britain gives green light for GSK Plc’s treatment of rare blood cancer

HQ Team April 18, 2025: Britain’s Medicines and Healthcare products Regulatory Agency has authorised GSK Plc’s combination drug to treat patients with multiple.

Read More
Johnson & Johnson’s combination therapy for treating a certain form of cancer without chemotherapy, has been shown to extend patients' lives by more than a year, according to a company statement.
Drugs Health Medical Pharma

J&J’s combination extends lives of cancer patients versus rival drug

Johnson & Johnson’s combination therapy for treating a certain form of cancer without chemotherapy, has been shown to extend patients' lives by more.

Read More
Merck & Co., Inc., announced it has met one of the primary goals during a late-stage trial of its breast cancer therapy, Keytruda.
Drugs Pharma

AstraZeneca, Merck announce promising results for breast cancer in trial 3

Bharti Jayshankar December 13, 2024: AstraZeneca and Merck have announced long-term results from the OlympiA Phase 3 trial, showing that Lynparza (olaparib) significantly.

Read More
Merck & Co., announced its trial drug along with a combination of the company’s Keytruda therapy failed to meet the main goal of overall survival in patients previously treated for a type of metastatic colorectal cancer. 
Drugs Health Pharma

Merck’s trial drug combination for colorectal cancer fails main goal

Merck & Co., announced its trial drug along with a combination of the company’s Keytruda therapy failed to meet the main goal of.

Read More